Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails
- PMID: 32439468
- PMCID: PMC7234946
- DOI: 10.1016/j.jaad.2020.04.177
Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails
Comment in
-
Response to: "Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails".J Am Acad Dermatol. 2020 Oct;83(4):e293. doi: 10.1016/j.jaad.2020.05.063. Epub 2020 May 19. J Am Acad Dermatol. 2020. PMID: 32439462 No abstract available.
Comment on
-
Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review.J Am Acad Dermatol. 2020 Aug;83(2):563-578. doi: 10.1016/j.jaad.2020.04.024. Epub 2020 Apr 11. J Am Acad Dermatol. 2020. PMID: 32289395
References
-
- Sharma A.N., Mesinkovska N.A., Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563–578. - PubMed
-
- Sifuentes Giraldo W.A., Grandal Platero M., de la Puente Bujidos C., Gámir Gámir M.L. Generalized skin hyperpigmentation and longitudinal melanonychia secondary to treatment with hydroxychloroquine in systemic lupus erythematosus. Reumatol Clin. 2013;9(6):381–382. - PubMed
-
- Zhang S., Liu X., Cai L., Zhang J., Zhou C. Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine. Lupus. 2019;28:129–132. - PubMed
-
- Bahloul E., Jallouli M., Garbaa S. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26:1304–1308. - PubMed
-
- Koch K., Tikly M. Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus. Lupus. 2019;28(8):1021–1026. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
